Acute Hepatic Porphyria (AHP)
Acute Hepatic Porphyria (AHP) is a group of rare genetic disorders caused by dysregulation of heme biosynthesis in the liver, leading to the accumulation of neurotoxic intermediates such as aminolevulinic acid (ALA) and porphobilinogen (PBG). It presents with acute, potentially life-threatening attacks, and may also cause chronic symptoms that negatively impact patient functioning and quality of life.
Resources
Infographics
Therapies
GIVLAARI® (givosiran)
Explore clinical and educational resources related to the use of vutrisiran in adult patients with polyneuropathy of ATTRv (also known as hATTR) amyloidosis or with cardiomyopathy of wild-type or ATTRv amyloidosis.
Congresses
Publications
Acute Hepatic Porphyria (AHP)
Patient experience with acute hepatic porphyria before and after long-term givosiran treatment in a qualitative interview study
Molecular Genetics and Metabolism Reports
